tbuckley/cabot-search huggingface dataset:
Abstract 8904: Predictors of Type 1 and Type 2 Myocardial Infarction
Authors: Ryan Wereski, Dorien M Kimenai, Anda Bularga, Caelan Taggart, David J Lowe, Nicholas L Mills, Andrew Chapman
Journal: Circulation (2021)

Background: Our understanding of the risk factors for myocardial infarction (MI) is limited to type 1 events caused by atherosclerotic plaque rupture and thrombosis. It is unclear whether similar risk factors are related to future type 2 MI events. Hypothesis: Cardiovascular disease risk factors are important in predicting type 2 MI Method: We conducted a secondary analysis of a multi-centre randomised trial population of 48,282 consecutive patients attending hospital with suspected acute coronary syndrome. Cox regression was used to identify predictors of future type 1 and type 2 MI during a one-year follow-up period. Results: During one-year of follow up 1,331 patients had a subsequent MI, with 924 and 407 adjudicated as type 1 and type 2 myocardial infarction, respectively. Risk factors for type 1 and type 2 MI were similar, with age, hyperlipidaemia, diabetes, increasing creatinine concentration, and known coronary disease important predictors for both (P&lt;0.05 for all). Whilst male sex is an established risk factor for type 1 MI, sex did not predict type 2 myocardial infarction (adjusted HR 0.82, 95% CI 0.66 to 1.01). The strongest predictor of type 2 MI was a prior history of type 2 events (aHR 6.18, 95% CI 4.70 to 8.12, Figure). Conclusions: Cardiovascular risk factors associated with type 1 MI are also important predictors of type 2 MI, suggesting common mechanisms including coronary disease are important. Treatment of these risk factors may reduce future susceptibility to both type 1 and type 2 MI.
Hematologic Recovery after Allogeneic Transplantation: Risk Factors and Its IMPACT on Transplant Related Mortality
Authors: Sabrina Giammarco, Carmen Di Grazia, Anna Maria Raiola, Stefania Bregante, Riccardo Varaldo, Francesca Gualandi, Simona Sica, Patrizia Chiusolo, Federica Sora, Luca Laurenti, Elisabetta Metafuni, Andrea Bacigalupo, Emanuele Angelucci
Journal: Blood (2021)
Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib
Authors: Constantine S. Tam, Emma Verner, Masa Lasica, Alejandro Arbelaez, Peter J. Browett, Jacob D. Soumerai, James Hilger, Yiqian Fang, Jane Huang, David Simpson, Stephen Opat, Chan Yoon Y. Cheah
Journal: Blood (2021)
Capturing the Lived Experiences of Women with Lymphoma in Pregnancy: An Australasian Lymphoma Alliance Study
Authors: Georgia Mills, Pietro R Di Ciaccio, Catherine Tang, Verity L Chadwick, Kylie D Mason, Belinda Campbell, Mohamed Shanavas, Kirk L Morris, Matthew Greenwood, Giselle Kidson-Gerber, Renee Eslick, Xavier Badoux, Costas K. Yannakou, Shane A Gangatharan, Nada Hamad
Journal: Blood (2021)
Racial and Ethnic Disparities in the Use of Prostate Magnetic Resonance Imaging Following an Elevated Prostate-Specific Antigen Test
Authors: Nino Abashidze, Chad Stecher, Andrew B. Rosenkrantz, Richard Duszak, Danny R. Hughes
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Prostate cancer screening and diagnosis exhibit known racial and ethnic disparities. Whether these disparities persist in prostate magnetic resonance imaging (MRI) utilization after elevated prostate-specific antigen (PSA) results is poorly understood. <h3>Objective</h3> To assess potential racial and ethnic disparities in prostate MRI utilization following elevated PSA results. <h3>Design, Setting, and Participants</h3> This cohort study of 794 809 insured US men was drawn from deidentified medical claims between January 2011 and December 2017 obtained from a commercial claims database. Eligible participants were aged 40 years and older and received a single PSA result and no prior PSA screening or prostate MRI claims. Analysis was performed in January 2021. <h3>Main Outcomes and Measures</h3> Multivariable logistic regression was used to examine associations between elevated PSA results and follow-up prostate MRI. For patients receiving prostate MRI, multivariable regressions were estimated for the time between PSA and subsequent prostate MRI. PSA thresholds explored included PSA levels above 2.5 ng/mL, 4 ng/mL, and 10 ng/mL. Analyses were stratified by race, ethnicity, and age. <h3>Results</h3> Of 794 809 participants, 51 500 (6.5%) had PSA levels above 4 ng/mL; of these, 1524 (3.0%) underwent prostate MRI within 180 days. In this sample, mean (SD) age was 59.8 (11.3) years (range 40-89 years); 31 350 (3.9%) were Asian, 75 935 (9.6%) were Black, 107 956 (13.6%) were Hispanic, and 455 214 (57.3%) were White. Compared with White patients, Black patients with PSA levels above 4 ng/mL and 10 ng/mL were 24.1% (odds ratio [OR], 0.78; 95% CI, 0.65-0.89) and 35.0% (OR, 0.65; 95% CI, 0.50-0.85) less likely to undergo subsequent prostate MRI, respectively. Asian patients with PSA levels higher than 4 ng/mL (OR, 0.76; 95% CI, 0.58-0.99) and Hispanic patients with PSA levels above 10 ng/mL (OR, 0.77; 95% CI, 0.59-0.99) were also less likely to undergo subsequent prostate MRI compared with White patients. Black patients between ages 65 and 74 years with PSA above 4 ng/mL and 10 ng/mL were 23.6% (OR, 0.76; 95% CI, 0.64-0.91) and 43.9% (OR, 0.56; 95% CI, 0.35-0.91) less likely to undergo MRI, respectively. Race and ethnicity were not significantly associated with mean time between PSA and MRI. <h3>Conclusions and Relevance</h3> Among men with elevated PSA results, racial and ethnic disparities were evident in subsequent prostate MRI utilization and were more pronounced at higher PSA thresholds. Further research is needed to better understand and mitigate physician decision-making biases and other potential sources of disparities in prostate cancer diagnosis and management.
First-Line Treatment and Survival of Stage I(E) Peripheral T-Cell Lymphoma in the Netherlands; A Nationwide Population-Based Cohort Study
Authors: Frederik O. Meeuwes, Mirian Brink, Marjolein W.M. Van Der Poel, Marie José Kersten, Mariëlle Wondergem, Pim G.N.J. Mutsaers, Lara H. Böhmer, F.J. Sherida H. Woei-a-Jin, Otto J. Visser, Rimke Oostvogels, Patty M. Jansen, Karen J. Neelis, Anne P.G. Crijns, Laurien A. Daniëls, Joost S.P. Vermaat, Gerwin A. Huls, Marcel Nijland
Journal: Blood (2021)
Identification of Shared and <scp>Asian‐Specific</scp> Loci for Systemic Lupus Erythematosus and Evidence for Roles of Type <scp>III</scp> Interferon Signaling and Lysosomal Function in the Disease: A <scp>Multi‐Ancestral Genome‐Wide</scp> Association Study
Authors: Yong‐Fei Wang, Wei Wei, Pattarin Tangtanatakul, Lichuan Zheng, Yao Lei, Zhiming Lin, Chengmin Qian, Xiao Qin, Fei Hou, Xinyu Zhang, Li Shao, Nusara Satproedprai, Surakameth Mahasirimongkol, Prapaporn Pisitkun, Qin Song, Yu Lung Lau, Yan Zhang, Nattiya Hirankarn, Wanling Yang
Journal: Arthritis & Rheumatology (2021)

Objective Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease with differences in prevalence and severity among ancestral groups. This study was undertaken to identify novel genetic components, either shared by or distinct between Asian and European populations. Methods Both trans‐ancestral and ancestry‐specific meta‐analyses of genome‐wide association studies (GWAS) for SLE were performed, involving 30,604 participants of European, Chinese, or Thai origin. Using public epigenomic data and expression quantitative trait loci, fine‐mapping analyses were conducted to identify putative causal variants and genes for the newly identified loci. Performance of polygenic risk scores for the Thai cohort was evaluated by comparing different training data. Results A 1‐bp deletion upstream of IFNLR1 was found to be associated with SLE, with the risk allele correlated with increased expression of IFNLR1 . This gene encodes interferon‐λ (IFNλ) receptor 1, providing evidence of a role of type III IFN signaling in SLE. An intronic variant in SLC29A3 was found to be associated with SLE in Asians only. The putative risk variant may modulate SLC29A3 expression in a monocyte‐specific manner. SLC29A3 encodes a lysosomal nucleoside transporter, and subsequent analyses suggested that reduced lysosomal function and phagocytosis might be the mechanism underlying this association. Ancestry‐shared loci in or near TAOK3 , CHD9 , CAMK1D , ATXN1 , and TARBP1 and Asian‐specific loci close to PEX2 , FCHSD2 , and TMEM116 also reached the genome‐wide significant association with SLE. In addition, trans‐ancestral meta‐analysis was shown to be valuable in risk prediction for individuals without ancestry‐matched data. Conclusion In this study both shared and Asian‐specific loci for SLE were identified, and functional annotation provided evidence of the involvement of increased type III IFN signaling and reduced lysosomal function in SLE.
Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy
Authors: Shipra Goel, Juan J. Gu, Pallawi Torka, Cory Mavis, Suchitra Sundaram, Mirdza Neiders, Lakshmanan Suresh, Long Shen, Vince Ramsperger, Elizabeth A. Griffiths, Brahm Segal, Francisco J. Hernandez-Ilizaliturri, Paola Ghione
Journal: Blood (2021)
Abstract PO-130: Macropinocytosis at the nexus of crosstalk in the pancreatic tumor microenvironment
Authors: Yijuan Zhang, M. Victoria Recouvreux, Michael Jung, Koen Galencamp, Yunbo Li, Olga Zagnitko, David Scott, Andrew Lowy, Cosimo Commisso
Journal: Cancer Research (2021)

Abstract A feature of tumor cells is the acquisition of nutrients via macropinocytosis, an endocytic form of protein scavenging that functions to support metabolism and proliferation in the context of a nutrient-depleted tumor microenvironment. Here, we provide evidence that macropinocytosis is also operational in the tumor stroma. We find that glutamine deficiency triggers macropinocytic uptake in patient-derived cancer-associated fibroblasts (CAFs) from pancreatic ductal adenocarcinoma (PDAC) tumors. Mechanistically, stromal macropinocytosis is dependent on a CaMKK2-AMPK signaling axis that activates Rac1. We find that these signaling events are potentiated via an enhancement of cytosolic Ca2+ caused by glutamine limitation. Interestingly, glucose deprivation, which robustly enhances AMPK activation, does not activate Rac1 and fails to induce uptake in CAFs. We determine that the selectivity of the observed macropinocytic response is mediated by the glutamine depletion-induced upregulation of ARHGEF2, a Rho/Rac guanine nucleotide exchange factor. We elucidate that macropinocytosis has dual function in CAFs – it serves as a source of intracellular amino acids that sustain CAF viability, and it provides extracellular amino acids that promote tumor cell survival. By specifically ablating macropinocytosis in the stroma, we demonstrate that macropinocytosis-deficient CAFs are unable to enhance PDAC tumor growth. Current efforts are focused on how different metabolic inputs in the tumor microenviroment can differentially regulate the CaMKK2-AMPK signaling axis in stromal cells. These results highlight the functional role of macropinocytosis in the tumor stroma and provide a mechanistic understanding of how nutrient deficiency can control stromal protein scavenging. Citation Format: Yijuan Zhang, M. Victoria Recouvreux, Michael Jung, Koen Galencamp, Yunbo Li, Olga Zagnitko, David Scott, Andrew Lowy, Cosimo Commisso. Macropinocytosis at the nexus of crosstalk in the pancreatic tumor microenvironment [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-130.
Whole Exome Sequencing in Severe Aplastic Anemia Identifies Unrecognized Inherited Subset with Inferior Survival after Hematopoietic Cell Transplant
Authors: Lisa J. McReynolds, Maryam Rafati, Youjin Wang, Bari Ballew, Valencia Owens, Jung Kim, Neal D. Freedman, Brian Carter, Sarah Strollo, Casey Dagnall, Belynda Hicks, Bin Zhu, Kristine Jones, Sophie Paczesny, Steven G.E. Marsh, Stephen R. Spellman, Stephanie J. Lee, Sharon A. Savage, Shahinaz M. Gadalla
Journal: Blood (2021)
Risk of lower respiratory tract infections: a genome-wide association study with Mendelian randomization analysis in three independent European populations
Authors: Helene M. Flatby, Humaira Rasheed, Anuradha Ravi, Laurent F. Thomas, Kristin V. Liyanarachi, Jan E. Afset, Andrew T. DeWan, Ben M. Brumpton, Kristian Hveem, Bjørn O. Åsvold, Gunnar S. Simonsen, Anne-Sofie Furberg, Jan K. Damås, Erik Solligård, Tormod Rogne
Journal: Clinical Microbiology and Infection (2021)

ObjectiveLower respiratory tract infections (LRTIs) are a leading cause of morbidity and mortality worldwide. Few studies have previously investigated genetic susceptibility and potential risk factors for LRTI.MethodsWe used data from the UK Biobank, Trøndelag Health Study (HUNT), and FinnGen to conduct a genome-wide association study (GWAS). Cases were subjects hospitalized with LRTI, and controls were subjects with no such hospitalization. We conducted stratification and interaction analyses to evaluate whether the genetic effect of LRTI differed by sex or smoking. Mendelian randomization (MR) analyses were conducted to identify the unconfounded relationship between cardiometabolic risk factors and LRTI.ResultsA total of 25 320 cases and 575 294 controls were included. The 15q25.1 locus reached genome-wide significance in the meta-analysis (rs10519203: OR 0.94, p 3.87e-11). The protective effect of effect allele of rs10519203 was present among smokers (OR 0.90, 95%CI 0.87–0.92, p 1.38e-15) but not among never-smokers (OR 1.01, 95%CI 0.97–1.06, p 5.20e-01). In MR analyses, we found that increasing body mass index (OR 1.31, 95%CI 1.24–1.40, p 3.78e-18), lifetime smoking (OR 2.83, 95%CI 2.34–3.42, p 6.56e-27), and systolic blood pressure robustly increased the risk of LRTIs (OR 1.11, 95%CI 1.02–1.22, p 1.48e-02).ConclusionA region in 15q25.1 was strongly associated with LRTI susceptibility. Reduction in the prevalence of smoking, overweight, obesity, and hypertension may reduce the disease burden of LRTIs.
Abstract 12306: Impact of the COVID Pandemic on Depression and Subsequent Emergency Department Visits for Anxiety and Chest Pain
Authors: Heidi T May, Tami L Bair, Viet T Le, Joseph B Muhlestein, Stacey Knight, Jeffrey L Anderson, Kirk U Knowlton, Benjamin D Horne
Journal: Circulation (2021)

Background: The COVID-19 pandemic has affected nearly every aspect of daily life. The interpersonal loss due to quarantining and social distancing, compounded with societal disruption has negatively affected mental health. Once established, mental health conditions can become chronic with having subsequent effects on additional risk factors and disease incidence, such as cardiovascular disease (CVD). Methods: Patients who completed a PHQ-9 in a primary care setting in the year prior to the COVID pandemic (Mar 1, 2019 to Feb 29, 2020) and during the COVID pandemic (Mar 1, 2020 to Apr 20, 2021) were studied. Patients were stratified into 2 groups: no depression/no longer depressed and remained depressed/became depressed. Patients were assessed for follow-up emergency department (ED) visits for anxiety and chest pain (CP) after PHQ-9 completion during the pandemic. Results: A total of 4,633 patients were studied, with 2,848 (61.5%) being never/no longer depressed and 1,785 (38.5%) remaining/became depressed. PHQ-9 scores during the pandemic were higher than prior to the pandemic among those depressed. A total of 2,171 (46.6%) received a COVID test, with more depressed patients tested compared to non-depressed (Table), but with positivity for SARS-CoV-2 (n=362 [16.7%]) being similar (p=0.18). The table shows baseline characteristics and outcomes. Depression was associated with increased ED visits for anxiety (Table). Those with depression, visited the ED at 3.5 times and 2.7 times greater rate for anxiety and anxiety with CP compared to non-depressed, respectively. Conclusions: Depression was highly prevalent among patients who receive routine primary care, with depressive symptoms increasing during the pandemic. Since depression and anxiety are associated with an increased risk of CVD and associated risk factors, identifying and treating patients early who exhibit such symptoms will be important in reducing the risk of future CVD and risk factor incidence.
Real-World Testing Patterns for Risk Assessment and Implications on the Adoption of Novel Therapeutics in Chronic Lymphocytic Leukemia: IGHV Mutation Status, FISH Cytogenetic, and Immunophenotyping
Authors: Asher Chanan-Khan, Keri Yang, Tom Liu, Todd Zimmerman, Boxiong Tang, Sikander Ailawadhi
Journal: Blood (2021)
Case 35-2021: A 50-Year-Old Woman with Pain in the Left Upper Quadrant and Hypoxemia
Authors: Margaret M. Chapman, Victorine V. Muse, James E. Mojica, Melis N. Anahtar
Journal: New England Journal of Medicine (2021)

A 50-year-old woman with sarcoidosis presented with pain in the left upper quadrant and hypoxemia. The oxygen saturation was 85% while she was breathing ambient air, and crackles were present in both lungs. Chest radiography revealed consolidations in the middle and lower lobes with diffuse ground-glass opacities. A diagnostic test was performed.
Clonal Dynamics of <i>JAK2</i>V617F and <i>Non-Driver</i> Mutations in Polycythemia Vera and Essential Thrombocythemia Patients Receiving Hydroxyurea Therapy
Authors: Lierni Fernández-Ibarrondo, Joan Gibert, Concepción Fernández-Rodríguez, Laura Camacho, Anna Angona, Marcio Andrade, Nieves Garcia-Gisbert, Leonor Arenillas, Patricia Vélez, Raquel Longarón, Ramon Diez-Feijoo, Antonio Salar, Carles Besses, Beatriz Bellosillo
Journal: Blood (2021)
Abstract 13627: Increasing Trend of Cannabis Use Disorder Among Young Patients Admitted Due to Acute Myocardial Infarction
Authors: Darshi Desai, Naima A Rahim, Cecilia Gadaga, Shrikanth Sampath, SHILPI SHARMA, Bahredin Abdella, Krupa Patel, Saral Desai, Abhinay Theli, Achint Patel, Zeeshan Mansuri
Journal: Circulation (2021)

Introduction: The prevalence of cannabis use disorder (CUD) has increased in the US especially following its legalization in various states. Few studies have reported that CUD has been associated with increased Acute Myocardial Infarction (AMI) especially in the younger population. There are limited epidemiological studies that estimate the recent trend of AMI among young patients with CUD. Hypothesis: To estimate the hospitalization trends of AMI with concurrent CUD and characteristics associated with it in the young population. Methods: Study cohort was derived from the National Inpatient Sample (NIS) for the years 2007-2018. Hospitalizations due to AMI among the age group of 18-49 and concurrent CUD were identified using previously validated ICD-9-CM/ICD-10-CM. We then utilized the Cochran Armitage trend test and multivariable survey logistic regression modeling to analyze temporal trends and predictors of CUD among AMI patients. Results: Out of a total 819,354 hospitalizations due to AMI among the age group of 18-49 years, 33,488 (4.1%) had concurrent CUD. Hospitalizations due to AMI with concurrent CUD increased from 1722 (2.4%) in 2007 to 4455 (6.7%) in 2018 with a 12% yearly rate (OR 1.1; 95%CI 1.1-1.1; p&lt;0.01). AMI patients with CUD were younger (20.2% vs 7.3%; p&lt;0.01), male (78.1.2% vs 71.6%; p&lt;0.01) and African American (35.2% vs 15.8%; p&lt;0.01). In multivariable regression analysis, age 18-34 (OR 2.9; 95% CI 2.7 - 3.1; P&lt;0.01), male (OR 1.5; 95%CI 1.4 - 1.6; p&lt;0.01), African American (OR 2.5; 95% CI 2.4-2.7, p&lt;0.01), Lower socio-economic status (OR 1.3; 95% CI 1.1-1.4, p&lt;0.01), West region (OR 1.3; 95% CI 1.2-1.5, p&lt;0.01), depression (OR 1.2; 95% CI 1.1-1.3, p &lt;0.01), alcoholism were associated with higher odds of CUD and AMI. Moreover, AMI patients with CUD were more likely to be admitted during the weekend (OR 1.1; CI 1.1-1.1, p &lt;0.01). Conclusions: Our study highlights the increasing trend of AMI hospitalizations with concurrent CUD. Our study also identifies that 18-34 years of age, male gender, African American and psychiatric conditions were significant determinants of CUD in young AMI patients. This warrants additional research to prove causal association between CUD and AMI in the young population in the era of increased cannabis legalization.
Abstract 10005: Sodium Intake and Risk of Cardiovascular Disease: A Pooled Analysis of Individual Data from Six Cohort Studies with Multiple 24-Hour Urine Collections
Authors: Yuan Ma, F J He, Qi Sun, Changzheng Yuan, Lyanne M Kieneker, Gary C Curhan, Graham A MacGregor, Stephan J Bakker, Norman Campbell, Molin Wang, Eric B Rimm, Joann Manson, Walter Willett, Albert Hofman, Ron T Gansevoort, Nancy R Cook, Frank B Hu
Journal: Circulation (2021)

Background: The relationship between sodium intake and cardiovascular disease (CVD) remains controversial, in part, due to inaccurate assessment of sodium intake. 24-hour urinary excretion over multiple days is considered the optimal method. Methods: We included individual participant data from 6 prospective cohorts among generally healthy adults with sodium and potassium excretion assessed by at least two 24-hour urine collections. Out of 10,709 participants (54% women; mean [SD] age, 51.5 [12.6] years), 571 incident CVD events (including myocardial infarction, coronary revascularization, and stroke) were ascertained during a median follow-up of 8.8 years. We analyzed each cohort using consistent methods and combined the results using random-effects meta-analysis. Results: Median 24-hour urinary sodium excretion (10 th -90 th percentile) was 3,270 (2,099-4,899) mg. Higher sodium excretion, lower potassium excretion and higher sodium-to-potassium ratio were all associated with higher risk of CVD events after controlling for confounding factors (all P values for trend≤0.02); there was no evidence of nonlinearity. The hazard ratio [HR] comparing top with bottom quartiles was 1.67 [95% confidence interval [CI]: 1.21-2.30] for sodium, 0.77 [0.57-1.02] for potassium and 1.72 [1.27-2.32] for sodium-to-potassium ratio. Each 1,000 mg/d increment in sodium excretion was associated with an 18% increase in CVD risk (95%CI: 5%-32%) and each 1,000 mg/d increment in potassium excretion was associated with 18% lower risk (95%CI: 6%-28%). Conclusions: Higher sodium and lower potassium intakes, measured in multiple 24-hour urine samples, were associated with higher risk of CVD in a dose-response manner. These findings support current recommendations to reduce sodium and increase potassium intakes.
Population-Based Surveillance of Pneumococcal Infections in Children with Sickle Cell Disease before and after Prevnar 7® and Prevnar 13® Licensure: Implications for Expanded Vaccination
Authors: Tom Adamkiewicz, Stephanie Thomas, Amy Tunali, Kristina Lai, Marianne McPherson Yee, Inci Yildirim, Peter Lane, Folashade Omole, Monica M. Farley
Journal: Blood (2021)
Making memories with Bcl-6
Authors: Kaitlin A. Read, Kenneth J. Oestreich
Journal: The Journal of Experimental Medicine (2021)

For over a decade, mutual antagonism between the transcriptional repressors Bcl-6 and Blimp-1 has been appreciated as a key mechanistic determinant of lymphoid differentiation programs. Now, in this issue of JEM, Ciucci et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20202343) demonstrate that this relationship is "central" to the generation of T cell memory.
P70.03 Computational Omics Biology Model (CBM) Identifies Amplifications of Chromosome 6p to Predict Chemotherapy Resistance
Authors: V. Velcheti, A.K. Ganti, A. Kumar, V. Patil, S. Khandelwal, R. S, K. S, N. Lunkad, V. S, Y. Narvekar, A. Pampana, N. Mundkur, S. Patel, L. Behura, R. Mandal, Y. Velkuru, V. Balakrishnan, J. Chauhan, P. G, N. Gupta, M. Patil, A. Prakash, R. Kr, D. Sahu, M. Castro
Journal: Journal of Thoracic Oncology (2021)